巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    MiMedx Group

    MDXG
    3.820
    0.250
    6.14%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・MiMedx Group - 延遲價格・最後更新於 24/06 12:15
    最高位
    4.170
    最低位
    3.810
    開市價
    --
    前收市價
    4.070
    成交量(千)
    59.46
    成交額(百萬)
    1.89
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    433.01
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    15.990 - 3.040
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    MiMedx Group
    證券代碼
    MDXG.US
    所屬板塊
    Biotechnology
    公司業務
    MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
    發行量
    112359601
    公司總部
    1775 West Oak Commons Court, NE
    公司網址
    https://www.mimedx.com
    公司電郵
    rborchert@mimedx.com
    公司電話
    +1 770 651-9100
    暫無內容

    關於

    MiMedx Group(MDXG.US)所屬的行業板塊為Biotechnology。
    MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
    詳細公司背景可參考: https://www.mimedx.com